The EPS beat suggests operational efficiency or cost control, which could be viewed positively by investors. However, the sales miss, especially with a significant year-over-year decrease, could raise concerns about growth prospects and demand for Karyopharm's products. This mixed result may lead to short-term volatility as the market digests the implications of both the earnings beat and the sales miss.